Text Size

Progression to Impaired Glucose Tolerance and Type 2 Diabetes in the Korean People-based KNDP Study

This study has been completed.
Sponsor:
Information provided by:
Korea University Guro Hospital
ClinicalTrials.gov Identifier:
NCT01034826
First received: December 17, 2009
Last updated: June 8, 2010
Last verified: December 2009
History of Changes
  Purpose

Impaired glucose tolerance is a metabolic state between normal glucose homeostasis and diabetes. Previously, prospective studies have shown higher progression rates from IGT to diabetes in other country. But There is no prospective-multicenter based reports in Korea. Therefore, the purpose of this study is to estimate the progression rates to impair glucose regulation and diabetes in the Korean population-based Korea national Diabetes program.


Condition
Impaired Glucose Tolerance
Diabetes

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Korea University Guro Hospital:

Primary Outcome Measures:
  • fasting serum glucose, fasting plasma insulin,post prandial serum glucose, post prandial plasma insulin, hbA1c [ Time Frame: 0.1.3.5 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: February 2007
Study Completion Date: May 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
life style modification
everyone in this study was advised about their life style, diet, exercise habits.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients who vist the endocrinology department due to impaired fasting glucose or impaired glucose tolerance, or both.

Criteria

Inclusion Criteria:

  • fastic serum glucose >100 and/or pp2 serum glucose <200

Exclusion Criteria:

  • known diabetes
  • organ failure(For example, liver, kidney)
  • known malignancy
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided by Korea University Guro Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Korea university Guro Hospital Endocrinology department, Korea university
ClinicalTrials.gov Identifier: NCT01034826     History of Changes
Other Study ID Numbers: KNDP IGT study
Study First Received: December 17, 2009
Last Updated: June 8, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by Korea University Guro Hospital:
NGT, IGT, diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Glucose Metabolism Disorders
 Metabolic Diseases
Endocrine System Diseases
Hyperglycemia

ClinicalTrials.gov processed this record on May 19, 2013